Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Primary Completion Date

June 30, 2012

Conditions

Allergic Conjunctivitis

Interventions

DRUG

DE-114 ophthalmic solution

DRUG

Placebo ophthalmic solution

DRUG

Olopatadine Hydrochloride 0.1% Ophthalmic Solution

Trial Locations (1)

Santen study sites, Osaka

All Listed Sponsors

lead

Santen Pharmaceutical Co., Ltd.

INDUSTRY

NCT01363700 - Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis | Biotech Hunter | Biotech Hunter